HCV | WEBCASTS

Beginning Date

12/21/2015

Ending Date

12/21/2016

1.0

credit

Speakers

David Wyles, MD
Associate Professor of Medicine
Division of Infectious Diseases
University of California, San Diego
San Diego, CA

Mark Sulkowski, MD
Medical Director, Viral Hepatitis Center
Professor of Medicine
Johns Hopkins Medical Center
Baltimore, MD

Webcast

Webcast must be viewed in its entirety to claim credit.

Accredited by:

This activity is provided by the Chronic Liver Disease Foundation.

This activity Supported by:

Merck & Co.

Program Overview

In this CME webcast, Dr. Mark Sulkowski and Dr. David Wyles provide their expert perspective on management of patients with chronic HCV. The webcast features an interactive discussion on recent clinical developments with current HCV treatments, an update on late-stage HCV treatment regimens and evidence-based recommendations on the management of HCV mono-infected and HIV/HCV co-infected patients.

Target Audience

This activity has been designed to meet the educational needs of hepatologists, gastroenterologists, infectious disease specialists, primary care providers, nurse practitioners/physician assistants and allied health care professionals by delivering a focused, educational update that highlights the most clinically relevant advances in the management of patients with HCV.

Educational Objectives

At the conclusion of this activity, participants will be able to:

•	Explain the current and emerging treatment options for patients with chronic hepatitis C
•	Recognize the baseline factors relevant for treatment decision making
•	Develop individualized, evidence-based treatment strategies with currently approved and soon to be approved regimens in order to optimize patient outcomes
•	Identify barriers to the optimal management of patients with chronic hepatitis C, including patients with HCV/HIV coinfection

Physician Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the University of Cincinnati and the Chronic Liver Disease Foundation (CLDF).

The University of Cincinnati is accredited by the ACCME to provide continuing medical education for physicians.

The University of Cincinnati designates this online activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credits commensurate with the extent of their participation in the activity.

Off Label Disclosure Statement:
Faculty members are required to inform the audience when they are discussing off-label, unapproved uses of devices and drugs. Physicians should consult full prescribing information before using any product mentioned during this educational activity.

It is the policy of The University of Cincinnati College of Medicine to ensure fair balance, independence, objectivity, and scientific rigor in all programming. All faculty and planners participating in sponsored programs are expected to identify and reference off-label product use and disclose any relationship with those supporting the activity or any others with products or services available within the scope of the topic being discussed in the educational presentation.

The University of Cincinnati College of Medicine assesses conflict of interest with its instructors, planners, managers, and other individuals who are in a position to control the content of CME/CE activities. All relevant conflicts of interest that are identified are thoroughly vetted by The University of Cincinnati College of Medicine for fair balance, scientific objectivity of studies utilized in this activity, and patient care recommendations. The University of Cincinnati College of Medicine is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in health care and not a specific proprietary business interest or a commercial interest.

In accordance with the ACCME Standards, parallel documents from other accrediting bodies, The University of Cincinnati College of Medicine policy, the following disclosures have been made: The faculty for this activity have disclosed that there will be discussion about the use of products for non-FDA approved indications. All staff at the University Of Cincinnati College Of Medicine have nothing to disclose.

Learner Assurance Statement:

The University of Cincinnati is committed to resolving all conflicts of interest issues that could arise as a result of prospective faculty members’ significant relationships with drug or device manufacturer(s). The University of Cincinnati is committed to retaining only those speakers with financial interests that can be reconciled with the goals and educational integrity of the CME activity.

Faculty Disclosures:

David Wyles, MD
Grants/Research Support: AbbVie, Bristol-Myers Squibb, Gilead, Merck, Tacere (All paid to institution.)
Advisory Board: Bristol-Myers Squibb, Gilead, Janssen, Merck

Mark Sulkowski, MD
Consultant: AbbVie, Bristol-Myers Squibb, Cocyrstal, Gilead, Janssen, Merck, Trek
Grant Recipient: AbbVie, Bristol-Myers Squibb, Gilead, Janssen, Merck
Advisory Board: AbbVie, Bristol-Myers Squibb, Cocyrstal, Gilead, Janssen, Merck, Trek

Planning Committee:

Lisa Pedicone, PhD - Planning Committee/Reviewer-No Relevant Relationships
Rick Ricer, MD, Professor - CME Compliance Reviewer-No Relevant Relationships
Barbara Forney, Program Manager - CME Compliance-No Relevant Relationships